FDA Inspection 1255022 — Aopline Health Industry Technology (Guangzhou) Co., Ltd.
The FDA completed an inspection of Aopline Health Industry Technology (Guangzhou) Co., Ltd. on Nov 8, 2024 in Guangzhou. The inspection was classified OAI (Official Action Indicated — regulatory and/or administrative actions are recommended). Product area: Drugs.
Inspection Details
- Classification
- Official Action Indicated (OAI)
- End Date
- Nov 8, 2024
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Guangzhou (China)